



8 November 2013
EMA/432613/2013
ENCEPP Secretariat

Draft agenda - 12th ENCePP Plenary Meeting

12 November 2013, 09.30 to 16.30, room 2A

Chairperson: Peter Arlett

Time	Item	Name
09.30	1. General Matters	
	1.1 Welcome and introductory remarks / Adoption of Agenda	Chair
09.40	2. Report from the Steering Group & Working Groups	
	2.1 Report from the ENCePP Steering Group <i>➤ The report will highlight key achievements 2012-2013, provide a summary of main changes to the SG and Plenary mandates, and include a reflection on PASS and the ENCePP E-Register/EU PAS Register</i>	Susana Perez-Gutthann
	2.2 Updates from ENCePP Working Group Chairs <i>➤ Reports on activities and mandates of all five active ENCePP working groups focussed on (1) key developments since the last Plenary (2) status of on-going work and (3) next steps</i>	Alejandro Arana, WG1 Laura Yates, WG2 Miriam Sturkenboom, WG3 Marlene Sinclair, WG HTA Nawab Qizilbash, WG DI
	2.3 Discussion / Q & A	ENCEPP Plenary
~11.00	COFFEE BREAK (30 minutes)	
11.30	3. Proposal for Industry Engagement	
	3.1 Proposal for further engagement with industry <i>➤ Report on follow-up discussions by SG to the meeting with industry held May 2013</i>	Morten Andersen
	3.2 Discussion	ENCEPP Plenary
12.15	4. Election of ENCePP Partners to the Steering Group	
	4.1 Explanation of election procedure	Thomas Goedecke
	4.2 Secret Ballot	ENCEPP Plenary
~12.30	LUNCH (60 minutes)	
13.30	4.3 Announcement of Election Results	Chair
13.35	5. Request for Collaboration <i>➤ Proposal for pharmacoepidemiology program at the Indian Council of Medical Research / Department of Health Research, Government of India</i>	Nilima A. Kshirsagar



Time	Item	Name
13.45	6. Session on Methodology – Pharmacogenomics <ul style="list-style-type: none"> ➤ <i>Each Plenary there is an interactive session on a particular methodology or population sub-group with a view to exploring the interface of the topic with the network as a whole. Previous topics have been e.g. pregnancy, the elderly and paediatrics. This time the focus is on pharmacogenomics which deals with the influence of genetic variation on drug response in patients.</i> 	
	6.1 Introductory remarks <ul style="list-style-type: none"> ➤ <i>Definitions</i> ➤ <i>EMA Pharmacogenomics Working Party</i> ➤ <i>Guidelines for consultation</i> 	Marisa Papaluca, EMA
	6.2 Pharmacogenomics – A Clinical Perspective	Munir Pirmohamed
	6.3 Pharmacogenomic methods - An Epidemiological Perspective	Olaf Klungel
	6.4 Pharmacogenomics, an important step in the quest for biomarkers of drug response	Bruno H. Stricker
	6.5 Discussion	ENCePP Plenary
~15.15	COFFEE BREAK (20 minutes)	
15.35	7. Publicly Funded Research	
	7.1 IMI – Future Calls	Hugh Lavery
	7.2 Overview: EMA funded drug safety studies	Kevin Blake
	7.3 Q & A / Discussion	ENCePP Plenary
16.20	Summary of discussions & next steps	Chair
	A.O.B	Chair
16.30	Close of meeting	